Antibacterial compound pbt2

Use of PBT2, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment and/or prophylaxis of a bacterial infection selected from the group consisting of:

• Neisseria gonorrhoeae, Neisseria meningitidis, nontypeable Haemophilus influenzae, Campylobacter and Helicobacter pylori infections.

Use of PBT2, or a pharmaceutically acceptable salt thereof, for the treatment and/or prophylaxis of a bacterial infection selected from the group consisting of:

• Neisseria gonorrhoeae, Neisseria meningitidis, nontypeable Haemophilus influenzae, Campylobacter and Helicobacter pylori infections.

A method for the treatment and/or prophylaxis of a bacterial infection selected from the group consisting of:

• Neisseria meningitidis, nontypeable Haemophilus influenzae, Campylobacter and Helicobacter pylori infections, in a subject, comprising administering an effective amount of PBT2, or a pharmaceutically acceptable salt thereof, to the subject.

Use of PBT2, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment and/or prophylaxis of a bacterial infection selected from the group consisting of:

• Neisseria meningitidis, nontypeable Haemophilus influenzae, Campylobacter and Helicobacter pylori infections.

Use of PBT2, or a pharmaceutically acceptable salt thereof, for the treatment and/or prophylaxis of a bacterial infection selected from the group consisting of:

• Neisseria meningitidis, nontypeable Haemophilus influenzae, Campylobacter and Helicobacter pylori infections.

The method or use of any one of the preceding claims, wherein PBT2, or a pharmaceutically acceptable salt thereof, is the sole active antibacterial agent.

The method or use of any one of the preceding claims, wherein PBT2, or a pharmaceutically acceptable salt thereof, is administered in the absence of zinc.

The method or use of any one of the preceding claims, wherein the PBT2, or a pharmaceutically acceptable salt thereof, is administered by a route selected from the group consisting of oral, systemic, topical, subcutaneous, intravenous, intraparenteral, intra-synovial, intravaginal, intraocular, transbuccal, transmucosal, and transdermal administration.

The method or use of any one of the preceding claims, wherein the PBT2, or a pharmaceutically acceptable salt thereof, is administered in the absence of both zinc and a further antibacterial agent.

The method or use of any one of the preceding claims, wherein PBT2, or a pharmaceutically acceptable salt thereof, is used or administered to the subject in an amount to achieve a peak blood concentration of between about 0.005 to about 25 mg/L, between about 0.005 to about 20 mg/L, between about 0.005 to about 15 mg/L, between about 0.005 to about 10 mg/L, between about 0.005 to about 5 mg/L, between about 0.005 to about 4 mg/L, between about 0.005 to about 3 mg/L, between about 0.01 to about 25 mg/L, between about 0.01 to about 20 mg/L, between about 0.01 to about 15 mg/L, between about 0.01 to about 10 mg/L, between about 0.01 to about 5 mg/L, between about 0.01 to about 4 mg/L, between about 0.01 to about 3 mg/L, between about 0.5 to about 25 mg/L, between about 0.5 to about 20 mg/L, between about 0.5 to about 15 mg/L, between about 0.5 to about 10 mg/L, between about 0.5 to about 5 mg/L, between about 0.5 to about 4 mg/L, between about 0.5 to about 3 mg/L, between about 1.0 to about 25 mg/L, between about 1.0 to about 20 mg/L. between about 1.0 to about 15 mg/L, between about 1.0 to about 10 mg/L, between about 1.0 to about 5 mg/L, between about 1.0 to about 4 mg/L, or between about 1.0 to about 3 mg/L.

The method or use of any one of the preceding claims, wherein the subject is a vertebrate animal, optionally a mammal, optionally a human subject in need of treatment and/or prophylaxis for said bacterial infection.

The method or use of any one of the preceding claims, wherein the Campylobacter is selected from the group consisting of:

• Campylobacter jejuni, Campylobacter coli, Campylobacter abortis, Campylobacter hepaticas, Campylobacter upsaliensis, Campylobacter helveticus and Campylobacter fetus.

The method or use of any one of the preceding claims, wherein the Campylobacter is Campylobacter jejuni.

A pharmaceutical composition comprising an effective amount of PBT2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the composition does not comprise zinc or a further antibacterial active.